Please assess the completion status of the following clinical trial:

Trial Title: A Triple Combination Therapy Study of Boceprevir, Pegasys and Copegus in Previously Untreated Patients With Genotype 1 Chronic Hepatitis C

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients \>/=18 years of age~* Chronic liver disease consistent with chronic hepatitis C, genotype 1 infection~* Serum HCV RNA quantifiable at screening~* Patients who have not been previously treated with pegylated interferon (IFN), standard IFN, RBV or any direct acting anti-viral agent~* Compensated liver disease (Child-Pugh Grade A clinical classification for patients with cirrhosis: total score \</=6)~* Negative urine or blood pregnancy test (for women of childbearing potential)~Exclusion Criteria:~* Women with ongoing pregnancy or breast feeding~* Male partners of women who are pregnant~* Therapy with any systemic anti-viral, anti-neoplastic or immunomodulatory treatment \</=6 months prior to the first dose of study drug~* Any investigational drug \</=6 weeks prior to the first dose of study drug~* History or other evidence of decompensated liver disease~* History or other evidence of a medical condition associated with chronic liver disease other than chronic hepatitis C~* Signs or symptoms of hepatocellular carcinoma~* Co-infection with HCV genotypes other than genotype 1~* Co-infection with hepatitis A, hepatitis B, and/or human immunodeficiency virus (HIV)~* Any patient with an increased risk for anemia~* History of severe psychiatric disease~* History of immunologically mediated, chronic pulmonary, or severe cardiac disease~* Current diseases that are not adequately controlled

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dual Combination Therapy (Type: EXPERIMENTAL): None
- Triple Combination Therapy (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).